Merck CEO Rob Davis
September 30, 2021 07:32 AM EDTUpdated 08:14 AM
Deals

Mer­ck, wad­ing even fur­ther in­to rare dis­ease, inks $11.5B deal for Ac­celeron and its po­ten­tial PAH block­buster

Kyle Blankenship

Con­firm­ing days of ru­mors and in­sid­er leaks, Mer­ck will ac­quire Ac­celeron Phar­ma and its lead PAH drug so­tater­cept for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times